Interventions du FILO à l'ASH 2024 dans le domaine de la LLC

RESIDUUM

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Poster présenté par Thérèse AURRAN-SCHLEINITZ

Result Type: Paper
Number: 4641
Presenter: Therese Aurran-Schleinitz
Program: Oral and Poster Abstracts
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
Time and Location:
Monday, December 11, 2023: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

ERADIC

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Poster présenté par Anne-Sophie MICHALLET

Result Type: Paper
Number: 3268
Presenter: Anne-Sophie Michallet
Program: Oral and Poster Abstracts
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
Time and Location:
Sunday, December 10, 2023: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

RESIST

Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group

Poster présenté par Loïc YSEBAERT

Result Type: Paper
Number: 3273
Presenter: Loic Ysebaert
Program: Oral and Poster Abstracts
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
Time and Location:
Sunday, December 10, 2023: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)